Evaluation of Pathwork Tissue of Origin (TOO) Test for Human Malignancies
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The pathworks tissue of origin test is a microarray-based test with the goal of identifying the tissue of origin in patients with metastatic tumors of unknown primary site.
| Condition | Intervention |
|---|---|
|
Neoplasm Metastasis |
Procedure: Pathwork TOO test |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Evaluation of Pathwork Tissue of Origin (TOO) Test for Human Malignancies |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients with a diagnosis of malignancy
Inclusion Criteria:1 Subjects must be at least 18 years old. The TOO test is designed to determine the tissue of origin of common adult malignancies. There are no gender/ethnic restrictions.
2 Patients with a diagnosis of malignancy established by pathologic review of H&E staining of tumor biopsy or tumor resection without definitive determination of tissue of origin as assessed by the PI. Samples must have been obtained within three months of enrollment, or the patient must still be under active evaluation for tissue of origin at the time of enrollment. There are no limitations on prior therapy and time from last prior therapy.
3 Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:1 Patients under the age of 18 are excluded. There are no exclusions based on gender/ethnicity.
2 There are no exclusion requirements due to co-morbid disease or incurrent illness, as needed.
3 Pregnancy or nursing participants will not be excluded from the study.
4 Patients with a diagnosis of leukemia including acute myelogenous leukemia, acute lymphocytic leukemia, hairy cell leukemia, chronic myelogenous leukemia and chronic lymphocytic leukemia are excluded from enrollment on this study. The TOO test does not cover these diagnoses.
Contacts and Locations| United States, California | |
| Stanford University School of Medicine | |
| Stanford, California, United States, 94305 | |
| Principal Investigator: | James L Zehnder | Stanford University |
More Information
No publications provided
| Responsible Party: | James L Zehnder, Stanford University School of Medicine |
| ClinicalTrials.gov Identifier: | NCT00977639 History of Changes |
| Other Study ID Numbers: | SU-03072008-1032, 98301, VAR0029 |
| Study First Received: | September 15, 2009 |
| Last Updated: | March 26, 2010 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Neoplasms Neoplasm Metastasis Neoplastic Processes Pathologic Processes |
ClinicalTrials.gov processed this record on May 23, 2013